Page 3 of 44
PH8.1-2 | PH8.1-2 | Antimicrobial Principles and Stewardship — SDL Guide — SDL Guide (Part 3)
Self-Assessment: Applying Antimicrobial Principles
Apply what you have learned through the following three scenarios. Think through each before checking the discussion.
Scenario A: A 60-year-old diabetic man presents with a 2-week history of productive cough and fever. Chest X-ray shows right lower lobe consolidation. He is admitted and receives intravenous ceftriaxone plus azithromycin. He improves within 48 hours, is afebrile, and able to eat. Sputum culture shows penicillin-sensitive Streptococcus pneumoniae. What should happen next, and why?
Discussion: This is an opportunity for both de-escalation (from ceftriaxone to oral amoxicillin) and IV-to-oral switch (given clinical improvement and oral tolerance). Azithromycin (added for atypical coverage) can be stopped once S. pneumoniae is confirmed. Total duration: 5 days from clinical stability. This is exemplary ASP practice.
Scenario B: Your institution's antibiogram shows 65% of E. coli UTI isolates are resistant to fluoroquinolones. A 25-year-old woman presents with uncomplicated UTI (no fever, not pregnant, no structural urinary abnormality). Your colleague prescribes ciprofloxacin 'because it's easy to take.' Is this appropriate? What would you prescribe?
Discussion: No — a 65% local resistance rate to fluoroquinolones makes empiric ciprofloxacin inappropriate for uncomplicated UTI in this setting. Appropriate alternatives: oral nitrofurantoin 100 mg modified-release BD × 5 days (preferred), or TMP-SMX if local resistance <20%, or fosfomycin 3g single dose. Reserve fluoroquinolones for complicated UTI and pyelonephritis where broader tissue penetration is needed.
Scenario C: An ICU patient with ventilator-associated pneumonia (VAP) is started on meropenem + amikacin. The clinical fellow asks if this combination 'prevents resistance.' What is the pharmacological rationale for — and the limitation of — this combination?
Discussion: The combination provides synergy for empiric cover of gram-negative VAP, including Pseudomonas (meropenem alone has a 15–25% resistance rate in many Indian ICUs). Amikacin (an aminoglycoside) has concentration-dependent activity and a PAE that complements meropenem's time-dependent β-lactam action. However, combination therapy does NOT reliably prevent emergence of resistance; it broadens initial coverage. Once the organism is identified and sensitive to meropenem alone, de-escalation to monotherapy is appropriate to reduce aminoglycoside toxicity.
CLINICAL PEARL
The dual duty of the antimicrobial prescriber: Every antibiotic order carries two responsibilities — therapeutic responsibility to the patient in front of you, and stewardship responsibility to every future patient who will need that antibiotic to work. When you prescribe a carbapenem for a simple UTI, you are not just undertreating the patient (a narrower drug would suffice) — you are contributing, even if infinitesimally, to the erosion of the last-resort drug class. The prescribers who best serve both duties are those who collect cultures, de-escalate promptly, respect treatment duration, and use hospital antibiograms rather than defaulting to the broadest agent available.